Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis

Drugs

Volumn 75, Issue 9, 2015, Pages 947-977

  Wiendl, Heinz ^a   Meuth, Sven G ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALEMTUZUMAB; ATORVASTATIN; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; COLECALCIFEROL; CURCUMIN; DACLIZUMAB; DIRUCOTIDE; FINGOLIMOD; FIRATEGRAST; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; LAQUINIMOD; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLATE MOFETIL; NATALIZUMAB; OPICINUMAB; PLACEBO; RITUXIMAB; SECUKINUMAB; TERIFLUNOMIDE; THIOCTIC ACID; UNINDEXED DRUG; USTEKINUMAB; IMMUNOSUPPRESSIVE AGENT; NEW DRUG;

ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DISABILITY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; EXPANDED DISABILITY STATUS SCALE; HUMAN; LONG TERM CARE; MENTAL DETERIORATION; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; DISABILITY EVALUATION; DRUGS, INVESTIGATIONAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS;

EID: 84930930111     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0411-0     Document Type: Article

References (130)

1. Kurtzke JF. A new scale for evaluating disability in multiple sclerosis. Neurology. 1955;5:580-3.
2. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-52.
3. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112(Pt 1):133-46.
4. Pfleger CC, Flachs EM, Koch-Henriksen N. Social consequences of multiple sclerosis (1): early pension and temporary unemployment - a historical prospective cohort study. Mult Scler. 2010;16:121-6.
5. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006;77:918-26.
6. Cohen JA, Reingold SC, Polman CH, et al. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol. 2012;11:467-76.
7. Amato MP, Fratiglioni L, Groppi C, et al. Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. Arch Neurol. 1988;45:746-8.
8. Francis DA, Bain P, Swan AV, et al. An assessment of disability rating scales used in multiple sclerosis. Arch Neurol. 1991;48:299-301.
9. Goodkin DE, Cookfair D, Wende K, et al. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group. Neurology. 1992;42:859-63.
10. Noseworthy JH, Vandervoort MK, Wong CJ, et al. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology. 1990;40:971-5.
11. Weinshenker BG, Rice GP, Noseworthy JH, et al. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain. 1991;114(Pt 2):1057-67.
12. Fischer JS, Rudick RA, Cutter GR, et al. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler. 1999;5:244-50.
13. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122(Pt 5):871-82.
14. Meyer-Moock S, Feng YS, Maeurer M, et al. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol. 2014;14:58.
15. Meuth SG, Bittner S, Ulzheimer JC, et al. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of neuroprotective and alternative treatment strategies. BioDrugs. 2010;24:317-30.
16. Ulzheimer JC, Meuth SG, Bittner S, et al. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies. BioDrugs. 2010;24:249-74.
17. European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis. 2015. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2015/03/WC500185161.pdf. Accessed 08 Apr 2015.
18. National Institute for Health and Care Excellence (NICE). Dimethyl fumarate for treating relapsing-remitting multiple sclerosis. NICE technology appraisal guidance 320. 2014. https://www.nice.org.uk/guidance/ta320/resources/guidance-dimethyl-fumarate-for-treating-relapsingremitting-multiple-sclerosis-pdf. Accessed 24 Feb 2015.
19. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278-86.
20. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387-401.
21. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:545-56.
22. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402-15.
23. ®. 2014. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022527s009lbl.pdf. Accessed 24 Feb 2015.
24. ®. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002202/WC500104528.pdf. Accessed 24 Feb 2015.
25. ®. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002514/WC500148682.pdf. Accessed 24 Feb 2015.
26. ®. 2014. http://products.sanofi.us/aubagio/aubagio.pdf. Accessed 26 Mar 2015.
27. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293-303.
28. Confavreux C, O'Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:247-56.
29. Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:977-86.
30. ®. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Public-assessment-report/human/002514/WC500148684.pdf. Accessed 24 Feb 2015.
31. Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler. 2014;20:705-16.
32. ®. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002601/WC500162069.pdf. Accessed 24 Feb 2015.
33. ®. 2014. https://www.tecfidera.com/pdfs/full-prescribing-information.pdf. Accessed 26 March 2015.
34. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087-97.
35. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098-107.
36. ®. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Public-assessment-report/human/002601/WC500162070.pdf. Accessed 24 Feb 2015.
37. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366:1000-9.
38. Vollmer TL, Sorensen PS, Selmaj K, et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol. 2014;261:773-83.
39. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416-26.
40. Leist TP, Comi G, Cree BA, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014;13:257-67.
41. European Medicines Agency. Withdrawal of the marketing authorisation application for Movectro (cladribine). 2011. http://www.ema.europa.eu/docs/en-GB/document-library/Medicine-QA/2011/02/WC500102304.pdf. Accessed 24 Feb 2015.
42. Massacesi L, Tramacere I, Amoroso S, et al. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One. 2014;9:e113371.
43. ®. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/003718/WC500150521.pdf. Accessed 24 Feb 2015.
44. ®. 2014. http://products.sanofi.us/lemtrada/lemtrada.pdf. Accessed 24 Feb 2015.
45. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819-28.
46. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829-39.
47. ®. 2014. http://www.tysabri.com/prescribingInfo. Accessed 26 March 2015.
48. ®. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000603/WC500044686.pdf. Accessed 24 Feb 2015.
49. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910.
50. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911-23.
51. ®. 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/019297s035lbl.pdf. Accessed 24 Feb 2015.
52. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry. 1997;62:112-8.
53. Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol. 1997;244:153-9.
54. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360:2018-25.
55. Edan G, Comi G, Le Page E, et al. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J Neurol Neurosurg Psychiatry. 2011;82:1344-50.
56. ®. 2014. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/020622s057lbl.pdf. Accessed 26 March 2015.
57. ®. 2014. https://www.medicines.org.uk/emc/medicine/17516. Accessed 24 Feb 2015.
58. Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013;73:705-13.
59. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1503-11.
60. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7:903-14.
61. O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8:889-97.
62. Lublin FD, Cofield SS, Cutter GR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013;73:327-40.
63. Center for Drug Evaluation and Research. Approval letter - interferon beta-1b. 1993. http://www.accessdata.fda.gov/drugsatfda-docs/nda/pre96/103471s0000-APPROV.pdf. Accessed 24 Feb 2015.
64. ® - authorisation details. 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000081/human-med-000673.jsp&mid=WC0b01ac058001d124. Accessed 26 March 2015.
65. ®. 2014. http://www.avonex.com/pdfs/Avonex-Prescribing-Information.pdf Accessed 26 March 2015.
66. ®. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000102/WC500029425.pdf. Accessed 24 Feb 2015.
67. ®.2014. http://emdserono.com/cmg.emdserono-us/en/images/Rebif%20PI-Jun2014-tcm115-19765.pdf?Version=. Accessed 26 March 2015.
68. ®. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000136/WC500048681.pdf. Accessed 24 Feb 2015.
69. ®. 2014. http://www.pharma.us.novartis.com/product/pi/pdf/extavia.pdf. Accessed 26 March 2015.
70. ®. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000933/WC500034701.pdf. Accessed 24 Feb 2015.
71. ®. 2014. http://labeling.bayerhealthcare.com/html/products/pi/Betaseron-PI.pdf. Accessed 26 March 2015.
72. ®. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000081/WC500053225.pdf. Accessed 24 Feb 2015.
73. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39:285-94.
74. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343:898-904.
75. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352:1498-504.
76. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology. 2002;59:1496-506.
77. Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther. 2007;29:2031-48.
78. De Stefano N, Curtin F, Stubinski B, et al. Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis. Mult Scler. 2010;16:888-92.
79. Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol. 2012;11:33-41.
80. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43:655-61.
81. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242-9.
82. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359:1453-60.
83. Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13:657-65.
84. ®. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002827/WC500170302.pdf. Accessed 24 Feb 2015.
85. Kieseier BC, Arnold DL, Balcer LJ, et al. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler. 2014. doi: 10.1177/1352458514557986.
86. Edan G, Kappos L, Montalban X, et al. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry. 2014;85:1183-9.
87. Kappos L, Selmaj K, Arnold DL, et al. Primary results of DECIDE: a randomized, double-blind, double-dummy, active-controlled trial of daclizumab HYP vs. Interferon β-1a in RRMS patients. Mult Scler. 2014;20(S1):38.
88. Biogen Idec Limited. Biogen Idec and AbbVie announce positive top-line results from phase 3 study investigating daclizumab high-yield process in multiple sclerosis. 2014. http://www.biogenidec.com/press-release-details.aspx?ID=14712&Action=1&NewsId=2358&M=NewsV2&PID=61997. Accessed 24 Feb 2015.
89. Beutler E, Sipe JC, Romine JS, et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA. 1996;93:1716-20.
90. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology. 2000;54:1145-55.
91. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66:460-71.
92. Freedman MS, Bar-Or A, Oger J, et al. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology. 2011;77:1551-60.
93. Pohlau D, Przuntek H, Sailer M, et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler. 2007;13:1107-17.
94. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet. 1998;352:1491-7.
95. Panitch H, Miller A, Paty D, et al. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63:1788-95.
96. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology. 2004;63:1779-87.
97. Montalban X, Sastre-Garriga J, Tintore M, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler. 2009;15:1195-205.
98. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology. 2001;56:1496-504.
99. Andersen O, Elovaara I, Farkkila M, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2004;75:706-10.
100. Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology. 2003;60:44-51.
101. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002;59:679-87.
102. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007;61:14-24.
103. Novartis Pharma AG. Novartis provides update on fingolimod Phase III trial in primary progressive MS (PPMS). 2014. http://www.novartis.com/newsroom/media-releases/en/2014/1875463.shtml. Accessed 26 March 2015.
104. Wiendl H, Hohlfeld R. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes. Neurology. 2009;72:1008-15.
105. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132:1175-89.
106. Freedman MS. Multiple sclerosis therapeutic strategies: use second-line agents as first-line agents when time is of the essence. Neurol Clin Pract. 2011;1:66-8.
107. Stys PK, Zamponi GW, van Minnen J, et al. Will the real multiple sclerosis please stand up? Nat Rev Neurosci. 2012;13:507-14.
108. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci. 2003;206:165-71.
109. Kutzelnigg A, Lassmann H. Pathology of multiple sclerosis and related inflammatory demyelinating diseases. Handb Clin Neurol. 2014;122:15-58.
110. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol. 2006;5:158-70.
111. Jacobsen C, Hagemeier J, Myhr KM, et al. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. J Neurol Neurosurg Psychiatry. 2014;85:1109-15.
112. Popescu V, Ran NC, Barkhof F, et al. Accurate GM atrophy quantification in MS using lesion-filling with co-registered 2D lesion masks. Neuroimage Clin. 2014;4:366-73.
113. Radue EW, Barkhof F, Kappos L, et al. Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology. 2015;84:784-93.
114. Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol. 2014;75:43-9.
115. De Stefano N, Airas L, Grigoriadis N, et al. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs. 2014;28:147-56.
116. Kalincik T, Jokubaitis V, Izquierdo G, et al. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.Mult Scler. 2014; doi: 10.1177/1352458514559865.
117. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355:1124-40.
118. Saida T, Kikuchi S, Itoyama Y, et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Mult Scler. 2012;18:1269-77.
119. Kira J, Itoyama Y, Kikuchi S, et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurol. 2014;14:21.
120. O'Connor PW, Li D, Freedman MS, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66:894-900.
121. Freedman MS, Wolinsky JS, Wamil B, et al. Teriflunomide added to interferon-beta in relapsing multiple sclerosis: a randomized phase II trial. Neurology. 2012;78:1877-85.
122. Remington GM, Treadaway K, Frohman T, et al. A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS). Ther Adv Neurol Disord. 2010;3:3-13.
123. Kamm CP, El-Koussy M, Humpert S, et al. Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial. PLoS One. 2014;9:e86663.
124. Torkildsen O, Wergeland S, Bakke S, et al. Omega-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Arch Neurol. 2012;69:1044-51.
125. Miller DH, Weber T, Grove R, et al. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2012;11:131-9.
126. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786-801.
127. Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008;7:796-804.
128. ®. 2007. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Scientific-Discussion/human/000603/WC500044690.pdf. Accessed 24 Feb 2015.
129. Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014;383:2213-21.
130. Vermersch P, Benrabah R, Schmidt N, et al. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol. 2012;12:36.